OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Eloy E. Ordaya, Elena Beam, Joseph D. Yao, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 7
Open Access | Times Cited: 17
Eloy E. Ordaya, Elena Beam, Joseph D. Yao, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 7
Open Access | Times Cited: 17
Showing 17 citing articles:
The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center
Mohanad Al‐Obaidi, Ahmet B. Gungor, Sandra Kurtin, et al.
The American Journal of Medicine (2022) Vol. 136, Iss. 1, pp. 96-99
Open Access | Times Cited: 42
Mohanad Al‐Obaidi, Ahmet B. Gungor, Sandra Kurtin, et al.
The American Journal of Medicine (2022) Vol. 136, Iss. 1, pp. 96-99
Open Access | Times Cited: 42
Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis
Arto Yuwono Soeroto, Theo Audi Yanto, Andree Kurniawan, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 2
Closed Access | Times Cited: 33
Arto Yuwono Soeroto, Theo Audi Yanto, Andree Kurniawan, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 2
Closed Access | Times Cited: 33
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 8
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 8
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
Saad Alhumaid, Abbas Al Mutair, Jalal Alali, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 118-118
Open Access | Times Cited: 24
Saad Alhumaid, Abbas Al Mutair, Jalal Alali, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 118-118
Open Access | Times Cited: 24
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
Rosaria Talarico, Giuseppe A. Ramirez, Sofia Barreira, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 5
Rosaria Talarico, Giuseppe A. Ramirez, Sofia Barreira, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 5
Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
D. Sindu, Deepika Razia, Katherine Grief, et al.
Transplantation Direct (2023) Vol. 9, Iss. 6, pp. e1485-e1485
Open Access | Times Cited: 5
D. Sindu, Deepika Razia, Katherine Grief, et al.
Transplantation Direct (2023) Vol. 9, Iss. 6, pp. e1485-e1485
Open Access | Times Cited: 5
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
Andrew Ustianowski
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 12, pp. 1517-1527
Closed Access | Times Cited: 6
Andrew Ustianowski
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 12, pp. 1517-1527
Closed Access | Times Cited: 6
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study
Giuseppe A. Ramirez, Maria Gerosa, Chiara Bellocchi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 3
Giuseppe A. Ramirez, Maria Gerosa, Chiara Bellocchi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 3
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
Raymund R. Razonable
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 7, pp. 619-631
Closed Access | Times Cited: 2
Raymund R. Razonable
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 7, pp. 619-631
Closed Access | Times Cited: 2
Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
Jowita Frączkiewicz, Katarzyna Pawińska-Wąsikowska, Katarzyna Szymbor, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2029-2029
Open Access
Jowita Frączkiewicz, Katarzyna Pawińska-Wąsikowska, Katarzyna Szymbor, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2029-2029
Open Access
Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak
Jianhua You, Jiaxin Tian, Haidi Wu, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 12, pp. 1365-1371
Closed Access | Times Cited: 1
Jianhua You, Jiaxin Tian, Haidi Wu, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 12, pp. 1365-1371
Closed Access | Times Cited: 1
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
Christopher Radcliffe, Maricar Malinis, Marwan M. Azar
Clinics in Chest Medicine (2022) Vol. 44, Iss. 2, pp. 279-297
Open Access | Times Cited: 2
Christopher Radcliffe, Maricar Malinis, Marwan M. Azar
Clinics in Chest Medicine (2022) Vol. 44, Iss. 2, pp. 279-297
Open Access | Times Cited: 2
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, et al.
HemaSphere (2023) Vol. 7, Iss. 5, pp. e880-e880
Open Access
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, et al.
HemaSphere (2023) Vol. 7, Iss. 5, pp. e880-e880
Open Access
Real-world experience of tixagevimab–cilgavimab in High-risk, immunocompromised coronavirus disease 2019 patients
NavinaKapur Birk, NanditaChanda Kapur, Henry Castellani, et al.
Deleted Journal (2023) Vol. 1, Iss. 3, pp. 239-241
Open Access
NavinaKapur Birk, NanditaChanda Kapur, Henry Castellani, et al.
Deleted Journal (2023) Vol. 1, Iss. 3, pp. 239-241
Open Access
